OSI Puts Eye Disease Franchise On The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Ongoing Macugen trials look promising, but OSI chooses to put its R&D funds into diabetes and oncology businesses, CEO tells analysts.